Use of immunohistochemistry in the diagnosis of problematic breast lesions

Journal of Clinical Pathology

Volumn 66, Issue 6, 2013, Pages 471-477

  Lee, Andrew H S ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CYTOKERATIN; ESTROGEN RECEPTOR; MYOSIN HEAVY CHAIN; PROTEIN P63; SMOOTH MUSCLE ACTIN; UVOMORULIN;

ATYPICAL DUCTAL HYPERPLASIA; BREAST CARCINOMA; BREAST LESION; BREAST METASTASIS; CELL PROLIFERATION; DIFFERENTIAL DIAGNOSIS; EPITHELIUM HYPERPLASIA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SPINDLE CELL CARCINOMA; TUMOR DIAGNOSIS;

BREAST; BREAST PATHOLOGY; IMMUNOHISTOCHEMISTRY;

ANTIBODY SPECIFICITY; BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; QUALITY CONTROL;

EID: 84878339431     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-201109     Document Type: Review

References (27)

1. Hilson JB, Schnitt SJ, Collins LC. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications. Am J Surg Pathol 2009;33:227-32.
2. Hilson JB, Schnitt SJ, Collins LC. Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesions of the breast. Am J Surg Pathol 2010;34:896-900.
3. Collins LC, Schnitt SJ. Papillary lesions of the breast: selected diagnostic and management issues. Histopathology 2008;52:20-9. (Pubitemid 350265188)
4. Geyer FC, Lacroix-Triki M, Colombo PE, et al. Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. Histopathology 2012;60:115-30.
5. Böcker W, Bier B, Freytag G, et al. An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part II: Epitheliosis and ductal carcinoma in situ. Virchows Archiv A Pathol Anat Histopathol 1992;421:323-30.
6. Otterbach F, Bankfalvi A, Bergner S, et al. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology 2000;37:232-40.
7. Shoker BS, Jarvis C, Sibson DR, et al. Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 1999;188:237-44. (Pubitemid 29317764)
8. Rakha EA, Teoh TK, Lee AHS, et al. Further evidence to support E-cadherin is not a tumour suppressor gene in invasive ductal carcinoma of the breast: an immunohistochemical study. Histopathology (in press).
9. Da Silva L, Parry S, Reid L, et al. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 2008;32:773-83. (Pubitemid 351600817)
10. Rakha EA, Patel A, Powe DG, et al. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol 2010;34:1472-9.
11. Acs G, Lawton TJ, Timothy R, et al. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 2001;115:85-98. (Pubitemid 33695094)
12. Giuliano AE, Hawes D, Ballman KV, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 2011;306:385-93.
13. Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 2011;364:412-21.
14. Gobbi H, Simpson JF, Borowsky A, et al. Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence. Cancer 1999;85:2170-82. (Pubitemid 29215556)
15. Sneige N, Yaziji H, Mandavilli SR, et al. Low-grade (fibromatosis-like). spindle cell carcinoma of the breast. Am J Surg Pathol 2001;25:1009-16. (Pubitemid 32685897)
16. Lee AHS. Recent developments in the histological diagnosis of spindle cell carcinoma, fibromatosis and phyllodes tumour of the breast. Histopathology 2008;52:45-57. (Pubitemid 350265183)
17. Chia Y, Thike AA, Cheok PY, et al. Stromal keratin expression in phyllodes tumours of the breast: a comparison with other spindle cell breast lesions. J Clin Pathol 2012;65:339-47.
18. Koker MM, Kleer CG. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol 2004;28:1506-12. (Pubitemid 39425518)
19. Leibl S, Gogg-Kammerer M, Sommersacher A, et al. Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol 2005;29:347-53. (Pubitemid 40321970)
20. Leibl S, Moinfar F. Mammary NOS-type sarcoma with CD10 expression: a rare entity with features of myoepithelial differentiation. Am J Surg Pathol 2006;30:450-6. (Pubitemid 43740145)
21. Lacroix-Triki M, Geyer FC, Lambros MB, et al. β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast. Mod Pathol 2010;23:1438-48.
22. McKenney JK, Weiss SW, Folpe AL. CD31 expression in intratumoral macrophages: a potential diagnostic pitfall. Am J Surg Pathol 2001;25:1167-73. (Pubitemid 32777716)
23. Sapino A, Bongiovanni M, Cassoni P, et al. Expression of CD31 by cells of extensive ductal in situ and invasive carcinomas of the breast. J Pathol 2001;194:254-61.
24. Lee AHS. The histological diagnosis of metastases to the breast from extramammary malignancies. J Clin Pathol 2007;60:1333-41. (Pubitemid 350247249)
25. Domfeh AB, Carley AL, Striebel JM, et al. WT1 immunoreactivity in breast carcinoma: selective expression in pure and mixed mucinous subtypes. Mod Pathol 2008;21:1217-23.
26. Perry KD, Reynolds C, Rosen DG, et al. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma. Histopathology 2011;59:619-30.
27. Chan ES, Alexander J, Swanson PE, et al. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms. Am J Surg Pathol 2012;36:737-43.